A specialized PET tracer has been developed to visualize the function of nerve cells that lead to neuronal loss and cognitive decline in neurodegenerative diseases. The tracer binds to a transporter of the neurotransmitter acetylcholine, allowing for the quantification of cholinergic neuron loss and its effects on cognition.
Researchers have developed three new MRI agents that successfully target the prostate-specific membrane antigen (PSMA) biomarker in multiple cancers. PSMA is found in both primary and metastatic prostate tumors, as well as in newly developing blood vessels of many non-prostate cancers.
The hybrid scanner combines conventional MRI, hyperpolarized MRI, positron imaging, luminescence imaging, and fluorescence microscopy to provide high-resolution multimodal intra-vital imaging. This allows researchers to study tumor biology and develop targeted therapies by analyzing the co-registration of multiple imaging data lines.
Researchers have developed a cloud-based software that analyzes and standardizes PET imaging data, allowing for earlier and more accurate diagnoses of Alzheimer's disease. The program uses machine learning to compare patients' scans with normal and abnormal scans, providing consistent results and quantifying PET data accurately.
A new technique combines dynamic PET imaging with parametric tumor mapping to detect tumors and metastases throughout the body, providing quantitative evaluation and improved contrast. This method has the potential to be used for early diagnosis and more accurate prognosis of various cancers.
Researchers used PET/CT with Ga-68 DOTATOC to detect primary tumors in patients with metastatic neuroendocrine cancer. The study found that 28% of patients underwent a major change in cancer management due to the imaging technique.
Research shows amyloid PET scans improve diagnosis and treatment outcomes for Alzheimer's patients, especially when used after an indeterminate FDG-PET scan. The study found that 17% of patients who received an amyloid scan experienced statistically significant improvements in cognition over a two-year follow-up.
Researchers developed PSMA-617, a theranostic drug that detects prostate cancer and targets enzyme on cancer cells. The technology shows substantial reduction in radiotracer uptake and significant decrease in PSMA in blood after therapy, indicating positive response.
A new theranostic agent, I-124 PEG-AVP0458, has shown promise in targeting both ovarian and prostate cancer cells for imaging and treatment. The drug compound attaches itself to the targeted tumor sites via positron emission tomography (PET) scanners, enabling personalized cancer therapy.
A novel PET technique tracks microglial activation in response to endotoxin, shedding light on neuroinflammatory diseases like Alzheimer's and depression. The study's findings could lead to new drug treatments by targeting immune dysfunction.
A new study found that PET/CT scans are highly sensitive for detecting relapsed non-Hodgkin lymphoma, with a sensitivity rate of 95.1%. This breakthrough has significant implications for patient care, as early diagnosis can lead to improved treatment outcomes and longer survival rates.
A new molecular imaging scan detects dangerous protein deposits in the heart, significantly increasing cardiac risk. The scan uses a widely available agent to assess amyloid buildup and predict future heart attacks.
A novel radionuclide drug, PSMA-617, has been developed to target prostate-specific membrane antigen (PSMA) on prostate cancer cells, allowing for personalized diagnosis and therapy. The drug showed promising results in a human clinical trial, with effective imaging and therapeutic effects.
Scientists have developed a novel PET tracer that can pinpoint thrombi throughout the body with over 97% accuracy. The tracer, Cu-64 FBP8, targets fibrin in blood clots and reflects thrombus age, enabling clinicians to choose more effective treatments.
Townsend's contributions to nuclear medicine have been transformative, introducing 3D PET imaging and the combined PET/CT scanner. His work has improved the signal-to-noise of reconstructed images without increasing detector material cost.
Phelps was recognized for his contributions to nuclear medicine and molecular imaging, including the invention of PET scanners. His work has improved outcomes for patients with cancer, neurological disorders, and cardiovascular disease.
A new non-invasive PET scan with C-11-vorozole detects aromatase in all body organs, potentially identifying cancer patients who may benefit from aromatase inhibitor treatment. The study also finds sex-dependent differences in radiation exposure and hormonal status.
A recent study found that the Ga-68-PSMA-ligand PET/CT detected a large number of positive findings in patients with biochemical recurrence after radical prostatectomy, particularly at low PSA-values. The tracer's higher detection rates compared to other imaging methods suggest an early detection advantage for further clinical management.
Researchers found PET/MR to be superior in diagnosing foot pain causes, providing more diagnostic information and higher certainty than PET/CT. This non-invasive method offers an important tool for sensitive diagnosis of foot pathologies.
Fourth and subsequent PET/CT scans improved clinical assessment and management change in lung cancer patients, with 52.28% positive and 47.7% negative results for recurrence or metastasis. The scans resulted in treatment changes in 28.1% of cases, with new treatments initiated in 20.4%.
A novel radioguided surgery technique using Y-90 DOTATOC can effectively identify residual cancer cells during brain tumor surgery, reducing healthy tissue removal. The study's findings suggest the potential for improved resection margins and enhanced patient outcomes.
Researchers develop a new approach to customize nuclear medicine treatment for cancer, using targeted alpha therapy with customized radiolabeled antibody cocktails. This method has great potential for treating various diseases, including those with disseminated tumor cells.
A new study shows a novel molecular imaging drug is effective in detecting early prostate cancer in soft tissue, lymph nodes, and bone. The drug, Tc-99m MIP-1404, has favorable pharmacokinetics and biodistribution, representing a breakthrough in prostate cancer imaging.
Researchers found that PET/CT imaging can help diagnose more aggressive tumors in young breast cancer patients, upstaging 21% of initial diagnoses. The study suggests considering patient age as a factor in staging decisions.
The Society of Nuclear Medicine and Molecular Imaging has announced the 2014-2016 Wagner-Torizuka Fellowship recipients, which provide two-year fellowships to support Japanese physicians in early stages of their careers. The fellows focus on functional imaging using modalities such as PET/CT and SPECT/CT to elucidate pathophysiology of...
A new study using PET/CT with FDG-labeled leucocytes has detected infection in acute pancreatitis patients, distinguishing between infected and non-infected fluid collections. This non-invasive method may quickly rule out active infection and guide treatment decisions.
The 2014 SNMMI Annual Meeting showcased over 100 scientific sessions, 750 oral presentations, and 1,155 posters on molecular imaging technologies, clinical applications, and translational research. The meeting also featured notable lectures and awards, including the Henry N. Wagner Jr. Lectureship and the Benedict Cassen Prize.
A new antibody-based molecular imaging agent has been developed to target the HER3 receptor in breast cancer, which may lead to better diagnosis and treatment of high-risk cases. This approach could also help identify patients who would benefit from additional therapies.
Researchers used a novel radioluminescence microscope to study single cells and found unexpected variation. The tool helps personalize radionuclide imaging by characterizing how radiotracers interact with cells.
Researchers used SPECT and PET systems to detect inflammation involved in osteoarthritis, giving doctors a clear read on chronic pain and possible joint destruction. Radiolabeled anti-FAP antibodies showed significantly increased imaging agent uptake in inflamed joints.
Scientists found a strong association between REM sleep disturbance and the development of progressive brain diseases like Parkinson's and dementia. Longitudinal imaging data showed decreased dopamine transporter density in patients with REM sleep disorder, which marked the first hints of Parkinson's disease.
Researchers used novel molecular imaging techniques to identify outlier cancer cells in the blood, which may indicate increased risk of metastases. The study found that less than 3% of circulating tumor cells showed abnormal glucose metabolism, suggesting potential aggressiveness.
A new study shows that administering G-CSF, a stem cell-stimulating therapy, early in the treatment of heart attack patients can improve their chances of survival and cardiac function. The therapy was found to increase blood flow, access to energy, and overall cardiac health.
A new molecular breast imaging protocol using a higher dose of Tc-99m filtered sulfur colloid has been shown to improve the detection of advanced breast cancer. Imaging performed the day prior to surgery was more sensitive than imaging on the day of surgery, detecting 76% versus 49% of cases with metastasized lymph nodes.
A new study reveals that PET/MR imaging is highly effective in detecting coronary artery disease, outperforming traditional SPECT methods. The hybrid technique provides a comprehensive view of the heart, combining anatomical and functional information for more accurate diagnoses.
A novel F-18 labeled tracer, F-18 THK5117, selectively binds to tau/neurofibrillary tangles in Alzheimer's brains. This study demonstrates the potential for F-18 THK5117 to develop new anti-dementia drugs.
Researchers developed a new concept to improve molecular imaging by co-injecting an NEP inhibitor, resulting in up to 40 times increased circulating radiopeptides and improved tumor uptake. This approach could lead to higher diagnostic sensitivity and therapeutic efficacy for cancer patients.
Researchers can conduct five different imaging studies in one scan with the Opti-SPECT/PET/CT system, providing comprehensive data on anatomy and physiological processes. The device allows for minimally invasive studies with a single dose of anesthesia, enabling scientists to develop new drug discovery methods.
Researchers link late-life depression to accelerated Alzheimer's disease development through beta-amyloid accumulation. Mild cognitive impairment patients with depressive symptoms showed higher amyloid deposition than non-depressed controls.
A new study reveals that combining SPECT/CT with conventional bone scans can provide accurate information about the source of low back pain, leading to more effective treatment. The results show that patients who underwent this imaging approach experienced significantly better pain relief outcomes compared to those who did not.
A new PSMA-based imaging agent, F-18 DCFBC PET/CT, has been developed to detect prostate cancer and monitor treatment response. The study shows the agent's effectiveness in detecting both castration-sensitive and castration-resistant forms of the disease.
A new therapy that combines chemotherapy with radiounclide treatment has shown promising results in slowing or stopping the progression of neuroendocrine cancer. In a study of 68 patients, the therapy resulted in stabilization or regression of the disease in 70% of cases, leading to improved patient survival rates.
A comprehensive clinical trial found that SPECT/CT imaging detected significantly more sentinel lymph node involvement with various types of cancers, including melanoma, breast carcinoma, and pelvic malignancies. This improved imaging technique has the potential to alter surgical planning and improve patient outcomes.
Siegel's work on PET has led to a major advance in nuclear medicine science, with a focus on evidence-based clinical trials and widespread acceptance of imaging studies. He is recognized for his visionary leadership in developing scientific methodology.
A study found that preoperative PET imaging reduced unnecessary surgeries for non-small cell lung cancer patients by 50%, eliminating approximately half of them. The use of PET increased during the study period, suggesting its potential to change policy and recommendations regarding tumor staging.
Researchers developed a radiopharmaceutical for identifying melanoma metastases, with higher sensitivity than FDG PET/CT. The treatment, using the same molecule as both a diagnostic and therapeutic agent, showed promising survival rates for patients.
Researchers used 18F-FDOPA PET imaging to differentiate between radiation-induced lesions and new tumor growth in brain metastases patients, achieving an accuracy of 83% with visual scoring. The study found that 18F-FDOPA PET imaging was highly prognostic of progression-free survival and overall survival.
New research published in The Journal of Nuclear Medicine found that radioembolization therapy can extend survival for patients with colorectal cancer liver metastases by approximately 50 percent. This treatment option has shown promise as a life-extending treatment for salvage patients who have failed current treatments.
Researchers identify markers that can predict rupture in abdominal aortic aneurysms, including dense white blood cells and C-reactive protein levels. The study suggests that PET/CT scans with positive uptake could provide diagnostic support for surgery, while negative uptake may indicate safe avoidance of unnecessary procedures.
Researchers used PET scans to identify hypermetabolism in the spine, indicating a potentially reversible phase of degenerative cervical myelopathy. Patients with this marker showed significant improvement after decompressive surgery, while those without exhibited no change.